ERBB2 and breast cancer: In contrast, Shen et al. revealed that HER2 heterogeneity, detected with a HER2 gene protein assay (GPA), was associated with poor overall survival (OS) and increased distal metastasis in patients with HER2-positive breast cancer [21,27].